Analysts at StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a note issued to investors on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
Titan Pharmaceuticals stock opened at $6.97 on Tuesday. The company has a 50-day simple moving average of $7.36 and a 200-day simple moving average of $7.16. The firm has a market capitalization of $6.34 million, a P/E ratio of -0.85 and a beta of 1.33. Titan Pharmaceuticals has a one year low of $5.00 and a one year high of $16.60.
About Titan Pharmaceuticals
Featured Articles
- Five stocks we like better than Titan Pharmaceuticals
- Trading Stocks: RSI and Why it’s Useful
- High-Yield Texas Instruments Could Hit New Highs Soon
- Options Trading – Understanding Strike Price
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.